1-(3-methoxyphenyl)-3-methylbutan-1-ol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(3-methoxyphenyl)-3-methylbutan-1-ol
• 化学式: C₁₂H₁₈O₂
• 分子量: 194.274
• InChiKey: KPGDRRJKWNRNKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(3-methoxyphenyl)-3-methylbutan-1-ol 、 盐酸 以53%的产率得到
  参考文献：
  名称：

  HARTMANN, R. W.;BUCHBORN, H.;KRANZFELDER, G.;SCHOENENBERGER, H.;BOGDEN, A+, J. MED. CHEM., 1981, 24, N 10, 1192-1197

  摘要：

  DOI：
• 作为产物：
  描述：

  3-甲氧基苯甲醛 以68%的产率得到
  参考文献：
  名称：

  HARTMANN R. W., J. MED. CHEM., 29,(1986) N 9, 1668-1674

  摘要：

  DOI：

文献信息

• Activation of Functional Arylzincs Prepared from Aryl Iodides and Highly Enantioselective Addition to Aldehydes
  作者：Albert M. DeBerardinis、Mark Turlington、Lin Pu

  DOI：10.1021/ol8008478

  日期：2008.7.3

  An easily available chiral ligand ( S)- 1 is found to activate the nucleophilic reaction of the arylzincs prepared in situ from the reaction of aryl iodides with Et(2)Zn. Both high yields and high enantioselectivity (up to >99% ee) for the reaction of these arylzincs with a variety of aldehydes are obtained. The mild reaction conditions and the good functional group tolerance make this catalytic asymmetric

  发现容易获得的手性配体（S）-1可以激活由芳基碘化物与Et（2）Zn的反应原位制备的芳基锌的亲核反应。这些芳基锌与各种醛的反应均获得了高收率和高对映选择性（高达> 99％ee）。温和的反应条件和良好的官能团耐受性使该催化不对称过程在合成上有用。
• NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS
  申请人：UNIVERSITY OF CINCINNATI

  公开号：US20160101188A1

  公开（公告）日：2016-04-14

  Compositions and methods for treating cancer in a subject are described herein. The composition includes modified nucleobases and nucleosides that are converted in the cell to nucleotides that are incorporated into growing DNA and result in termination of DNA elongation. The nucleobases and nucleotides are incorporated with a drug delivery system (DDS). The DDS includes β-cyclodextrin. The nucleobases and nucleotides are conjugated to the β-cyclodextrin by an acid labile linker that releases the nucleobases and nucleotides in the acidic environment of cancer cells. The DDS may also include a targeting ligand that targets the DDS/nucleobase or nucleotide conjugate to cancer cells. The DDS/nucleobase or nucleotide conjugate may self form into nanoparticles and may be administered to a subject with cancer in an amount effective to treat said cancer.

  本文描述了用于治疗患者癌症的组合物和方法。该组合物包括经过修饰的核碱基和核苷，这些核碱基和核苷在细胞中转化为核苷酸，并被合并到正在生长的DNA中，导致DNA延伸终止。这些核碱基和核苷与药物输送系统（DDS）一起使用。DDS包括β-环糊精。核碱基和核苷通过酸敏链连接到β-环糊精上，该链在癌细胞的酸性环境中释放核碱基和核苷。DDS还可以包括靶向配体，将DDS/核碱基或核苷共轭物靶向癌细胞。DDS/核碱基或核苷共轭物可以自行形成纳米粒子，并可以以有效治疗癌症的剂量给患者服用。
• [EN] NOVEL NANOCARRIER DELIVERED CANCER CHEMOTHERAPEUTIC AGENTS<br/>[FR] NOUVEAUX AGENTS CHIMIOTHÉRAPEUTIQUES ANTICANCÉREUX DÉLIVRÉS PAR NANO-PORTEUR
  申请人：UNIV CINCINNATI

  公开号：WO2014194250A2

  公开（公告）日：2014-12-04

  Compositions and methods for treating cancer in a subject are described herein. The composition includes modified nucleobases and nucleosides that are converted in the cell to nucleotides that are incorporated into growing DNA and result in termination of DNA elongation. The nucleobases and nucleotides are incorporated with a drug delivery system (DDS). The DDS includes β-cyclodextrin. The nucleobases and nucleotides are conjugated to the β-cyclodextrin by an acid labile linker that releases the nucleobases and nucleotides in the acidic environment of cancer cells. The DDS may also include a targeting ligand that targets the DDS/ nucleobase or nucleotide conjugate to cancer cells. The DDS/ nucleobase or nucleotide conjugate may self form into nanoparticles and may be administered to a subject with cancer in an amount effective to treat said cancer.